H5 N-terminal β sheet promotes oligomerization of H7-HA1 that induces better antibody affinity maturation and enhanced protection against H7N7 and H7N9 viruses compared to inactivated influenza vaccine

Vaccine

Volumn 32, Issue 48, 2014, Pages 6421-6432

  Khurana, Surender ^a   Coyle, Elizabeth M ^a   Verma, Swati ^a   King, Lisa R ^a   Manischewitz, Jody ^a   Crevar, Corey J ^b   Carter, Donald M ^b   Ross, Ted M ^b   Golding, Hana ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b Vaccine and Gene Therapy Institute of Florida   (United States)

Author keywords

Affinity; Antibody; Bacteria; Ferrets; H7N7; H7N9; HA1; Hemagglutinin; Immune Response; Influenza; Pandemic; Protein; Vaccine

Indexed keywords

INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; MONOMER; NEUTRALIZING ANTIBODY; OLIGOMER; OLIGOMERIC H7 HA1 PROTEIN; POLYMER; SUBUNIT VACCINE; TRIMER; UNCLASSIFIED DRUG; VIRUS ANTIBODY; INACTIVATED VACCINE;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY AFFINITY; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BETA SHEET; CONTROLLED STUDY; ESCHERICHIA COLI; EXPERIMENTAL RABBIT; FEMALE; FERRET; HUMAN; HUMAN CELL; INFECTION CONTROL; INFLUENZA VACCINATION; INFLUENZA VIRUS A H7N7; INFLUENZA VIRUS A H7N9; LETHALITY; NONHUMAN; OLIGOMERIZATION; PANDEMIC INFLUENZA; RECEPTOR BINDING; TREATMENT OUTCOME; VACCINE PRODUCTION; VIRUS HEMAGGLUTINATION; VIRUS IMMUNITY; VIRUS LOAD; VIRUS NEUTRALIZATION; WEIGHT REDUCTION; WILD TYPE; ANIMAL; BLOOD; HEMAGGLUTINATION TEST; IMMUNOLOGY; INFLUENZA A VIRUS (H5N1); INFLUENZA A VIRUS (H7N7); INFLUENZA A VIRUS (H7N9); ORTHOMYXOVIRIDAE INFECTIONS; PROTEIN MULTIMERIZATION; PROTEIN TERTIARY STRUCTURE; RABBIT;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY AFFINITY; FEMALE; FERRETS; HEMAGGLUTINATION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA A VIRUS, H7N7 SUBTYPE; INFLUENZA A VIRUS, H7N9 SUBTYPE; INFLUENZA VACCINES; ORTHOMYXOVIRIDAE INFECTIONS; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, TERTIARY; RABBITS; VACCINES, INACTIVATED;

EID: 84908572326     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.09.049     Document Type: Article

References (20)

1. Khurana S., Larkin C., Verma S., Joshi M.B., Fontana J., Steven A.C., et al. Recombinant HA1 produced in E. coli forms functional oligomers and generates strain-specific SRID potency antibodies for pandemic influenza vaccines. Vaccine. 2011, 29:5657-5665.
2. Khurana S., Verma S., Verma N., Crevar C.J., Carter D.M., Manischewitz J., et al. Properly folded bacterially expressed H1N1 hemagglutinin globular head and ectodomain vaccines protect ferrets against H1N1 pandemic influenza virus. PLoS ONE. 2010, 5:e11548.
3. Khurana S., Verma S., Verma N., Crevar C.J., Carter D.M., Manischewitz J., et al. Bacterial HA1 vaccine against pandemic H5N1 influenza virus: evidence of oligomerization, hemagglutination, and cross-protective immunity in ferrets. J Virol. 2010, 85:1246-1256.
4. Verma S., Dimitrova M., Munjal A., Fontana J., Crevar C.J., Carter D.M., et al. Oligomeric recombinant H5 HA1 vaccine produced in bacteria protects ferrets from homologous and heterologous wild-type H5N1 influenza challenge and controls viral loads better than subunit H5N1 vaccine by eliciting high-affinity antibodies. J Virol. 2012, 86:12283-12293.
5. Gao R., Cao B., Hu Y., Feng Z., Wang D., Hu W., et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med. 2013, 368:1888-1897.
6. Zhu H., Wang D., Kelvin D.J., Li L., Zheng Z., Yoon S.W., et al. Infectivity, transmission, and pathology of human-isolated H7N9 influenza virus in ferrets and pigs. Science. 2013, 341:183-186.
7. Watanabe T., Kiso M., Fukuyama S., Nakajima N., Imai M., Yamada S., et al. Characterization of H7N9 influenza A viruses isolated from humans. Nature. 2013, 501:551-555.
8. Li Q., Zhou L., Zhou M., Chen Z., Li F., Wu H., et al. Epidemiology of human infections with avian influenza A(H7N9) virus in China. N Engl J Med. 2014, 370:520-532.
9. Smith G.E., Flyer D.C., Raghunandan R., Liu Y., Wei Z., Wu Y., et al. Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus. Vaccine. 2013, 31:4305-4313.
10. Dormitzer P.R., Suphaphiphat P., Gibson D.G., Wentworth D.E., Stockwell T.B., Algire M.A., et al. Synthetic generation of influenza vaccine viruses for rapid response to pandemics. Sci Transl Med. 2013, 5:185ra68.
11. Khurana S., Verma N., Yewdell J.W., Hilbert A.K., Castellino F., Lattanzi M., et al. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci Transl Med. 2011, 3:85ra48.
12. Khurana S., Verma N., Talaat K.R., Karron R.A., Golding H. Immune response following H1N1pdm09 vaccination: differences in antibody repertoire and avidity in young adults and elderly populations stratified by age and gender. J Infect Dis. 2011, 205:610-620.
13. Capua I. Avian influenza: We have the chance to make a difference. Vet J. 2007, 174:213-214.
14. Koopmans M., Wilbrink B., Conyn M., Natrop G., van der Nat H., Vennema H., et al. Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet. 2004, 363:587-593.
15. Couch R.B., Patel S.M., Wade-Bowers C.L., Nino D. A randomized clinical trial of an inactivated avian influenza A (H7N7) vaccine. PLoS One. 2012, 7:e49704.
16. Zhang Q., Shi J., Deng G., Guo J., Zeng X., He X., et al. H7N9 influenza viruses are transmissible in ferrets by respiratory droplet. Science. 2013, 341:410-414.
17. Bos M.E., Te Beest D.E., van Boven M., van Beest Holle M.R., Meijer A., Bosman A., et al. High probability of avian influenza virus (H7N7) transmission from poultry to humans active in disease control on infected farms. J Infect Dis. 2010, 201:1390-1396.
18. Yang H., Carney P.J., Donis R.O., Stevens J. Structure and receptor complexes of the hemagglutinin from a highly pathogenic H7N7 influenza virus. J Virol. 2012, 86:8645-8652.
19. Wei C.J., Xu L., Kong W.P., Shi W., Canis K., Stevens J., et al. Comparative efficacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from avian H5N1 influenza virus. J Virol. 2008, 82:6200-6208.
20. Weldon W.C., Wang B.Z., Martin M.P., Koutsonanos D.G., Skountzou I., Compans R.W. Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin. PLoS ONE 2009, 2009.